SGLT2 inhibitors were subsequently approved for CKD in 2021 and received a Class I recommendation for treating HF with reduced ejection fraction (HFrEF) per the American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) guidelines in 2022 [12,13]. Here, SLC5A2 is linked to chronic kidney disease.